Insights
Search Results
Client Highlights
5.05.26
Wilson Sonsini Represents Investors in Windward Bio’s $165 Million Crossover Financing
On May 4, 2026, Windward Bio, a private, clinical-stage biotechnology company committed to improving outcomes for people living with serious immunological diseases, announced an upsized $165 million crossover financing led by OrbiMed, with participation from existing Series A investors including Novo Holdings, Blue Owl Healthcare Opportunities, SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan Capital, and Pivotal bioVenture Partners. The financing also included new investors RA Capital Management, Janus Henderson Investors, Sanofi Ventures, and Harbour BioMed. Wilson Sonsini Goodrich & Rosati represented OrbiMed, Novo Holdings, Blue Owl Healthcare Opportunities, and Omega Funds in the transaction.
Since its launch in January 2025, Windward Bio has in-licensed two clinical-stage assets, raised $365 million, and rapidly advanced both programs in the clinic. The proceeds from this latest financing will significantly extend the company’s cash runway and enable multiple clinical readouts in the next 12 months.
The Wilson Sonsini team that represented OrbiMed, Novo Holdings, Blue Owl Healthcare Opportunities, and Omega Funds in connection with the financing included:
Since its launch in January 2025, Windward Bio has in-licensed two clinical-stage assets, raised $365 million, and rapidly advanced both programs in the clinic. The proceeds from this latest financing will significantly extend the company’s cash runway and enable multiple clinical readouts in the next 12 months.
The Wilson Sonsini team that represented OrbiMed, Novo Holdings, Blue Owl Healthcare Opportunities, and Omega Funds in connection with the financing included:
Client Highlights
4.09.26
Wilson Sonsini Advises Forte Biosciences on $150 Million Public Offering
On April 8, 2026, Forte Biosciences, Inc., a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, announced the pricing of a public offering of 5,709,936 shares of its common stock at a price to the public of $26.27 per share. The gross proceeds from the offering are expected to be approximately $150 million before deducting underwriting discounts and commissions and other offering expenses. Wilson Sonsini Goodrich & Rosati advised Forte Biosciences on the transaction.
Client Highlights
3.13.26
Wilson Sonsini Advises Urgently on Acquisition by Agero
On March 13, 2026, Agero, a software-enabled driver safety services and technology company, announced that it has entered into an agreement to acquire Urgent.ly (Urgently), a digital software platform that provides roadside and mobility assistance, for a cash price of $5.50 per share. The tender offer and merger are expected to close by the end of May 2026, subject to satisfaction of customary closing conditions. Wilson Sonsini Goodrich & Rosati advised Urgently on the transaction.
Client Highlights
2.23.26
Firm Advises Arcellx on $7.8 Billion Acquisition by Gilead
On February 23, 2026, Gilead Sciences announced that it has entered into a definitive agreement to acquire Arcellx, a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases, for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Wilson Sonsini Goodrich & Rosati advised Arcellx on the transaction.
Client Highlights
12.15.25
Wilson Sonsini Advises Quantum Computing on $110 Million Acquisition of Luminar Semiconductor
On December 15, 2025, Quantum Computing (QCi), an innovative, quantum optics and integrated photonics technology company, announced that it has signed an agreement to acquire Luminar Semiconductor (LSI), a wholly owned subsidiary of Luminar Technologies, in an all-cash transaction valued at $110 million, subject to customary adjustments. Wilson Sonsini Goodrich & Rosati is advising QCi on the transaction
Client Highlights
10.20.25
Wilson Sonsini Advises Lexeo Therapeutics on $153.8 Million Underwritten Public Offering and Concurrent Private Placement
On October 20, 2025, Lexeo Therapeutics, a clinical-stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced the closing of its previously announced underwritten public offering and concurrent private placement, for total gross proceeds to Lexeo of approximately $153.8 million, before deducting underwriting discounts and commissions and other expenses. Wilson Sonsini Goodrich & Rosati represented Lexeo in the transaction.
Client Highlights
7.30.25
Wilson Sonsini Advises ImmunityBio on Execution of $80 Million Equity Financing
On July 25, 2025, ImmunityBio, a biotechnology company developing therapies that bolster the natural immune system to defeat cancers and infectious diseases, announced it has executed financing to provide further working capital and support its ongoing business operations. The company entered into a securities purchase agreement for a registered direct offering with two institutional investors, providing for the issuance of common stock of ImmunityBio as well as warrants for the purchase of additional shares of common stock of ImmunityBio that is expected to result in gross proceeds at closing of approximately $80 million before deducting placement agent fees and other offering-related expenses, subject to customary closing conditions. If fully exercised, the warrants could result in additional gross proceeds of up to approximately $96 million. Wilson Sonsini Goodrich & Rosati advised ImmunityBio on the transaction.
The Wilson Sonsini team advising ImmunityBio includes:
Corporate
Patents and Innovations
For more information, please see ImmunityBio’s press release.
Client Highlights
6.02.25
Wilson Sonsini Advises Lexeo Therapeutics on $80 Million Private Placement Equity Financing
On May 28, 2025, Lexeo Therapeutics, a clinical-stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, closed its previously announced $80 million private placement equity financing. Wilson Sonsini Goodrich & Rosati advised Lexeo on the transaction.
Client Highlights
2.28.25
Wilson Sonsini Advises Urgent.ly on Debt Restructuring and New $20 Million Revolving Credit Facility
On February 26, 2025, Urgent.ly, a U.S.-based leading provider of digital roadside and mobility assistance technology and services, announced that it reached an agreement with its lenders resulting in significant capital structure improvements. Urgent.ly entered into a new credit agreement for an asset-based revolving credit facility for up to $20 million with MidCap Financial, which will be used to repay existing indebtedness and to help the company advance its mission to transform the legacy roadside assistance market and to develop and define the new market for connected mobility assistance services for automotive, insurance, fleet, logistics, new mobility, and technology transportation companies.
Client Highlights
1.28.25
Wilson Sonsini Advises Ascentage Pharma on U.S. Initial Public Offering and Nasdaq Listing
On January 28, 2025, Ascentage Pharma Group International announced the closing of its U.S. initial public offering of 7,325,000 American depositary shares (ADSs) at a public offering price of $17.25 per ADS, before underwriting discounts and commissions. Each ADS represents four ordinary shares of Ascentage Pharma. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Ascentage Pharma, were approximately $126.4 million. In addition, Ascentage Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,098,750 ADSs at the initial public offering price, less underwriting discounts and commissions. The ADSs began trading on the Nasdaq Global Market on January 24, 2025.
Client Highlights
8.02.24
Wilson Sonsini Advises Aurora on $483 Million Upsized Public Offering
On August 2, 2024, Aurora Innovation, Inc., a self-driving vehicle technology company, announced the closing of its underwritten upsized public offering for total gross proceeds of approximately $483 million, before deducting underwriting discounts and commissions and other offering expenses. In the public offering, Aurora sold 134,166,667 shares of its Class A common stock at $3.60 per share, which includes the full exercise by the underwriters of their option to purchase up to 17,500,000 additional shares.
Client Highlights
6.21.24
Wilson Sonsini Advises Ascentage Pharma on HK$585.77 Million (US$75 Million) Equity Investment from Takeda International in Connection with the Exclusive Global License for HQP1351 (olverembatinib)
Ascentage Pharma Group International (Ascentage Pharma) and Takeda Pharmaceuticals International AG (Takeda International) entered into an exclusive option agreement on June 14, 2024, where Takeda International is granted with an exclusive option to enter into an exclusive license agreement for HQP1351 (olverembatinib), a core drug candidate of Ascentage Pharma. In connection with such exclusive global arrangement, Ascentage Pharma and Takeda International also entered into a securities purchase agreement, pursuant to which Takeda International made a HK$585.77 million (US$75 million) equity investment in Ascentage Pharma to subscribe 24,307,322 shares of Ascentage Pharma at a purchase price of HK$24.09850 per share. The closing of such equity investment took place on June 20, 2024.